Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase I...

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials
2017-06-22
Sihuan voluntary announcement establishment of joint venture on minimally-invasive aesthetic products

The board of directors (the “Board”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company” or “Sihuan Pharmaceutical” together with its subsidiaries, the “Group”) announces that Sun Mora...

2017-03-29
Sihuan Pharmaceutical Announces 2016 Annual Results

Sihuan Pharmaceutical Announces 2016 Annual Results, \"Forging Ahead from a Solid Foundation\"

2016-12-15
CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Pate

CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug – FadanafilHONG KONG, 14 December 2016, – Sihuan Pharmaceutical ...

2016-11-01
Successful listing of LIDE Biotech, invested by Sihuan Pharmaceutical in form of equity participation

Successful listing of LIDE Biotech, invested by Sihuan Pharmaceutical in form of equity participation

2016-09-27
Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

Total 11 Pages  First page  Page up  Page down  Last page

Select

  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012